ArticleLeukemia2016
Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment.
Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Skin Responses in Newly Diagnosed Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome After Therapy With Low-Dose Lenalidomide Plus Dexamethasone.Frontiers in immunology · 2021Trial
- Autologous stem cell transplantation in POEMS syndrome: Multicenter real-world treatment patterns and outcomes.Bone marrow transplantation · 2026Article
- POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management.American journal of hematology · 2026Review
- Prognostic value of the neutrophil-to-lymphocyte ratio in POEMS syndrome.Clinical and experimental medicine · 2026Article
- A rare coexistence of immunoglobulin light chain amyloidosis and POEMS syndrome manifesting as refractory heart failure: a case report and literature review.Frontiers in immunology · 2026Review
- POEMS syndrome: diagnosis, treatments, and outcomes.Hematology. American Society of Hematology. Education Program · 2025Article
- Successful treatment with carfilzomib and dexamethasone for relapsed/refractory POEMS syndrome: a case report and review of literature.Frontiers in oncology · 2025Article
- Case Report: Secondary myelodysplastic syndrome following autologous stem cell transplantation in a patient with POEMS syndrome.Frontiers in immunology · 2025Article
- Long-term outcomes of newly diagnosed POEMS syndrome patients who received first-line lenalidomide-based therapy.Haematologica · 2024Article
- A Multicenter Analysis of Clinical Features and Long-Term Outcomes of POEMS Syndrome in Korea.Journal of Korean medical science · 2024Article
- Case report: DKRd regimen in the treatment of newly diagnosed POEMS syndrome and literature review.Frontiers in oncology · 2024Article
- Treatment and outcome of second-line therapy for POEMS syndrome after autologous stem cell transplantation.Bone marrow transplantation · 2023Article
- Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience.Blood cancer journal · 2023Article
- Surgical revascularization for quasi-moyamoya disease associated with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome: a case report and literature review.Nagoya journal of medical science · 2023Review
- Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma.Blood advances · 2022Article
- Update on the POEMS syndrome.Blood research · 2022Review
- Leave It to the Prose: A Case of POEMS Syndrome.Cureus · 2021Article
- Mass cytometry identifies expansion of double positive and exhausted T cell subsets in the tumour microenvironment of patients with POEMS syndrome.British journal of haematology · 2020Article
- POEMS syndrome: clinical update.Journal of neurology · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although clinical improvement is almost universal with therapy in patients with POEMS (an acronym for polyneuropathy, organomegaly, endocrinopathies, monoclonal protein and a variety of skin changes) syndrome, outcomes and management of patients who relapse or progress (R/P) after first-line treatment have not been described. We retrospectively identified 262 patients with POEMS syndrome treated at the Mayo Clinic from 1974 to 2014 and who had follow-up information. The 5-year progression-free survival (PFS) and overall survival (OS) was 58% and 78%, respectively. Median time to R/P was 42 months. Seventy-nine patients (30%) had an R/P, with 52 (19%) experiencing a symptomatic R/P. Eighteen patients relapsed with symptoms or signs that were not documented at diagnosis. Median times to vascular endothelial growth factor, hematologic, radiographic and clinical R/P were 35 months (range, 4-327 months), 72 months (range, 4-327 months), 51 months (range, 4-327 months) and 48 months (range, 6-311 months), respectively. On multivariate analyses, low albumin at diagnosis and failure to achieve a complete hematologic response to first-line therapy were independent risk factors for PFS. Thirty patients had documentation of a second R/P at a median of 26 months from diagnosis of the first R/P. An early R/P was a risk factor for death, but most patients with an R/P had salvageable disease. A majority of patients are still without R/P at 5 years from diagnosis.
Indexed as
Identifiers
26669974What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.